NAGE
Niagen Bioscience, Inc.
3.10$
+1.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 38.6% | 39.0% | 39.3% | 39.8% | 36.5% | 37.5% | 36.6% | 35.0% | 35.5% | 35.9% | 36.5% | 35.2% | 35.8% | |
| 61.4% | 61.0% | 60.7% | 60.2% | 63.5% | 62.5% | 63.4% | 65.0% | 64.5% | 64.1% | 63.5% | 64.8% | 64.2% | |
| 6.4% | 5.5% | 9.5% | 5.8% | 5.0% | 4.5% | 4.1% | 5.0% | 5.3% | 5.1% | 4.7% | 5.1% | 5.0% | |
| 30.0% | 25.6% | 24.2% | 24.9% | 24.6% | 3.6% | 17.0% | 23.4% | 21.0% | 22.1% | 23.0% | 23.4% | 22.3% | |
| 67.3% | 61.8% | 64.0% | 61.3% | 57.2% | 38.1% | 47.8% | 54.8% | 52.1% | 57.9% | 58.5% | 62.5% | 57.6% | |
| -5.9% | -0.8% | -3.3% | -1.1% | 6.3% | 24.4% | 15.7% | 10.2% | 12.5% | 6.2% | 5.0% | 2.4% | 6.7% | |
| -4.9% | 0.5% | -2.2% | -0.1% | 7.3% | 25.7% | 17.2% | 12.0% | 14.1% | 13.1% | 21.4% | 3.6% | 13.2% | |
| – | – | – | – | – | 1.0% | 0.6% | 0.4% | 0.7% | 0.9% | 1.3% | 0.4% | 0.8% | |
| -4.9% | 0.5% | -2.2% | -0.1% | 7.3% | 24.6% | 16.6% | 11.6% | 13.5% | 12.2% | 20.1% | 3.2% | 12.4% | |
| -2.6% | 2.3% | -0.5% | 1.6% | 8.8% | 26.9% | 18.4% | 13.2% | 14.7% | 15.6% | 22.3% | 3.9% | 14.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.